Treatment of multiple sclerosis with Anti-CD20 antibodies

Clinical Immunology

Volumn 142, Issue 1, 2012, Pages 31-37

  Barun, Barbara ^a,b   Bar Or, Amit ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Anti CD20; B cells; Multiple Sclerosis; Therapy

Indexed keywords

BETA1A INTERFERON; CD20 ANTIGEN; DIPHENHYDRAMINE; FLUDARABINE; METHOTREXATE; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PARACETAMOL; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VELTUZUMAB;

ADD ON THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; HEART FAILURE; HOT FLUSH; HUMAN; HYPOTENSION; LUNG INSUFFICIENCY; LYMPHOCYTE DEPLETION; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84856297433     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.04.005     Document Type: Review

References (37)

1. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 1980, 125:1678-1685.
2. Bubien J.K., Zhou L.J., Bell P.D., Frizzell R.A., Tedder T.F. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 1993, 121:1121-1123.
3. Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15:450-454.
4. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood 1994, 84(8):2457-2466.
5. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424-1433.
6. Press O.W., Howell-Clark J., Anderson S., Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994, 83:1390-1399.
7. Cragg M.S., Walshe C.A., Ivanov A.O., Glennie M.J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 2005, 8:140-174.
8. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83(2):435-445.
9. Deans J.P., Li H., Polyak M.J. CD20-mediated apoptosis: signaling through lipid rafts. Immunology 2002, 107:176-182.
10. Paues J., Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J. Clin. Virol. 2010, 48(4):291-293.
11. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun. Rev. 2008, 8(2):144-146.
12. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
13. van Meerten T., Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin. Hematol. 2010, 47:199-210.
14. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63(3):395-400.
15. Naismith R.T., Piccio L., Lyons J.A., Lauber J., Tutlam N.T., Parks B.J., Trinkaus K., Song S.K., Cross A.H. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010, 74(23):1860-1867.
16. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358(7):676-688. HERMES Trial Group.
17. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66(4):460-471. OLYMPUS trial group.
18. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., Calabresi P.A., Waubant E., Hauser S.L., Zhang J., Smith C.H. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67(4):452-461.
19. Kausar F., Mustafa K., Sweis G., Sawaqed R., Alawneh K., Salloum R., Badaracco M., Niewold T.B., Sweiss N.J. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin. Biol. Ther. 2009, 9(7):889-895.
20. Kappos L, Calabresi P, O'Connor P, Bar-Or A, Li D, Barkhof F, Yin M, Glanzman R, Tinbergen J, Hauser S. Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis: Results of a Phase II Randomized Placebo-Controlled Multicenter Trial. ECTRIMS, 13-16 OCTOBER 2010, GÖTEBORG, SWEDEN; manuscript submitted.
21. Zhang B. Ofatumumab. MAbs 2009, 1(4):326-331.
22. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177:362-371.
23. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
24. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G., Parren P.W., Taylor R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009, 183:749-758.
25. Traynor K. Ofatumumab approved for advanced CLL. Am. J. Health Syst. Pharm. 2009, 1(66):2062.
26. Østergaard M., Baslund B., Rigby W., Rojkovich B., Jorgensen C., Dawes P.T., Wiell C., Wallace D.J., Tamer S.C., Kastberg H., Petersen J., Sierakowski S. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010, 62(8):2227-2238.
27. Soelberg Sorensen P, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS)-24-week results of a phase II study. ECTRIMS; October 13-16, 2010; Gothenburg, Sweden. P136.
28. Monson N.L., Cravens P.D., Frohman E.M., Hawker K., Racke M.K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 2005, 62(2):258-264.
29. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180(1-2):63-70.
30. Petereit H.F., Moeller-Hartmann W., Reske D., Rubbert A. Rituximab in a patient with multiple sclerosis-effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol. Scand. 2008, 117(6):399-403.
31. Piccio L., Naismith R.T., Trinkaus K., Klein R.S., Parks B.J., Lyons J.A., Cross A.H. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67(6):707-714.
32. Martin Mdel P., Cravens P.D., Winger R., Kieseier B.C., Cepok S., Eagar T.N., Zamvil S.S., Weber M.S., Frohman E.M., Kleinschmidt-Demasters B.K., Montine T.J., Hemmer B., Marra C.M., Stüve O. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch. Neurol. Aug 2009, 66(8):1016-1020.
33. Bouaziz J.D., Yanaba K., Venturi G.M., Wang Y., Tisch R.M., Poe J.C., Tedder T.F. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(52):20878-20883.
34. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 2008, 118(10):3420-3430.
35. Weber M.S. Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann. Neurol. 2010, 68(3):369-383.
36. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. May 15 2007, 178(10):6092-6099.
37. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J. Immunol. Mar 15 2004, 172(6):3422-3427.